VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence

Journal of Interferon and Cytokine Research

Volumn 20, Issue 5, 2000, Pages 511-517

  Stoelcker, Benjamin ^a   Echtenacher, Bernd ^a   Weich, Herbert A ^b   Sztajer, Helena ^b,c   Hicklin, Daniel J ^d   Männel, Daniela N ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASCITES; ASCITES FLUID; BINDING SITE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; IMMUNOPATHOGENESIS; INHIBITION KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ASCITES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MICE; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECURRENCE; RNA, MESSENGER; RNA, NEOPLASM; SARCOMA, EXPERIMENTAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA;

EID: 0034091396     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/10799900050023933     Document Type: Article

References (39)

1. 1. SENGER, D.R., VAN DE WATER, L., BROWN, L.F., NAGY, J.A., YEO, K.T., YEO, T.K., BERSE, B., JACKMAN, R.W., DVORAK, A.M., and DVORAK, H.F. (1993). Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12, 303-324.
2. 2. SENGER, D.R., GALLI, S.J., DVORAK, A.M., PERRUZZI, C.A., HARVEY, V.S., and DVORAK, H.F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
3. 3. CONNOLLY, D.T., HEUVELMAN, D.M., NELSON, R., OLANDER, J.V., EPPLEY, B.L., DELFINO, J.J., SIEGEL, N.R., LEIMGRUBER, R.M., and FEDER, J. (1989). Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84, 1470-1478.
4. 4. McCLURE, N., HEALY, D.L., ROGERS, P.A., SULLIVAN, J., BEATON, L., HANING, R.V., Jr., CONNOLLY, D.T., and ROBERTSON, D.M. (1994). Vascular endothelial growth factor as capillary permeability agent in ovarian hyperStimulation syndrome. Lancet 344, 235-236.
5. 5. FAVA, R.A., OLSON, N.J., SPENCER GREEN, G., YEO, K.T., YEO, T.K., BERSE, B., JACKMAN, R.W., SENGER, D.R., DVORAK, H.F., and BROWN, L.F. (1994). Vascular permeability factor/ endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. 180, 341-346.
6. 6. WEINDEL, K., MORINGLANE, J.R., MARME, D., and WEICH, H.A. (1994). Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? Neurosurgery 35, 439-448.
7. 7. YEO, K.T., WANG, H.H., NAGY, J.A., SIOUSSAT, T.M., LEDBETTER, S.R., HOOGEWERF, A.J., ZHOU, Y., MASSE, E.M., SENGER, D.R., and DVORAK, H.F. (1993). Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 53, 2912-2918.
8. 8. CRISCUOLO, G.R. (1993). The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. Yale J. Biol. Med. 66, 277-314.
9. 9. MILLAUER, B., SHAWYER, L.K., PLATE, K.H., RISAU, W., and ULLRICH, A. (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367, 576-579.
10. 10. MILLAUER, B., LONGHI, M.P., PLATE, K.H., SHAWYER, L.K., RISAU, W., ULLRICH, A., and STRAWN, L.M. (1996). Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56, 1615-1620.
11. 11. KIM, K.J., LI, B., WINER, J., ARMANINI, M., GILLETT, N., PHILLIPS, H.S., and FERRARA, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
12. 12. WARREN, R.S., YUAN, H., MATLI, M.R., GILLETT, N.A., and FERRARA, N. (1995). Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789-1797.
13. 13. CHENG, S.Y., HUANG, H.J., NAGANE, M., JI, X.D., WANG, D., SHIH, C.C., ARAP, W., HUANG, C.M., and CAVENEE, W.K. (1996). Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc. Natl. Acad. Sci. US A 93, 8502-8507.
14. 14. SKOBE, M., ROCKWELL, P., GOLDSTEIN, N., VOSSELER, S., and FUSENIG, N.E. (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. 3, 1222-1227.
15. 15. LUO, J.C., TOYODA, M., and SHIBUYA, M. (1998). Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res. 58, 2594-2600.
16. 16. RÄTH, U., KAUFMANN, M., SCHMID, H., HOFMANN, J., WIEDEMANN, B., KIST, A., KEMPENI, J., SCHLICK, E., BASTERT, G., and KOMMERELL, B. (1991). Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur. J. Cancer 27, 121-125.
17. 17. BEHAMMER, W., KLUGE, M., RÜSCHOFF, J., and MÄNNEL, D.N. (1996). Tumor necrosis factor effects on ascites formation in an experimental tumor model. J. Interferon Cytokine Res. 16, 403-408.
18. 18. GOUGH, N.M. (1988). Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells. Anal. Biochem. 173, 93-95.
19. 19. WEINDEL, K., MARME, D., and WEICH, H.A. (1992). AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem. Biophys. Res. Commun. 183, 1167-1174.
20. 20. BREIER, G., ALBRECHT, U., STERRER, S., and RISAU, W. (1992). Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114, 521-532.
21. 21. ROCKWELL, P., NEUFELD, G., GLASSMAN, A., CARON, D., and GOLDSTEIN, N. (1995). In vitro neutralization of vascular endothelial growth factor activaiton of Flk-1 by a monoclonal antibody. Mol. Cell. Differ. 3, 91-109.
22. 22. KENDALL, R.L., and THOMAS, K.A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705-10709.
23. 23. ROECKL, W., HECHT, D., SZTAJER, H., WALTENBERGER, J., YAYON, A., and WEICH, H.A. (1998). Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp. Cell Res. 241, 161-170.
24. 24. LEEK, R.D, HARRIS, A.L., and LEWIS, C.E. (1994). Cytokine networks in solid human tumors: regulation of angiogenesis. J. Leukocyte Biol. 56, 423-435.
25. 25. SHIBUYA, M., LUO, J.C., TOYODA, M., and YAMAGUCHI, S. (1999). Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother. Pharmacol. 43, S72-S77.
26. 26. FAJARDO, L.F., KWAN, H.H., KOWALSKI, J., PRIONAS, S.D., and ALLISON, A.C. (1992). Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol. 140, 539-544.
27. 27. PIGUET, P.F., GRAU, G.E., and VASSALLI, P. (1990). Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am. J. Pathol. 136, 103-110.
28. 28. FRATER SCHRÖDER, M., RISAU, W., HALLMANN, R., GAUTSCHI, P., and BOHLEN, P. (1987). Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA 84, 5277-5281.
29. 29. OTT, M.G., MÄNNEL, D.N., GALLATI, H., GOERIG, M., and RAETH, U. (1996). Peripheral natural killer cell activity and intraperitoneal soluble p55 tumor necrosis factor receptor in patients with malignant ascites: two possible indicators for response to intraperitoneal combined tumor necrosis factor alpha and interferon gamma treatment. Cancer Immunol. Immunother. 42, 31-37.
30. 30. ROSENTHAL, R.A., MEGYESI, J.F., HENZEL, W.J., FERRARA, N., and FOLKMAN, J. (1990). Conditioned medium from mouse sarcoma 180 cells contains vascular endothelial growth factor. Growth Factors 4, 53-59.
31. 31. BARLEON, B., HAUSER, S., SCHOLLMANN, C., WEINDEL, K., MARME, D., YAYON, A., and WEICH, H.A. (1994). Differential expression of the two VEGF receptors Flt and KDR in placenta and vascular endothelial cells. J. Cell Biochem. 54, 56-66.
32. 32. PATTERSON, C., PERRELLA, M.A., ENDEGE, W.O., YOSHIZUMI, M., LEE, M.E., and HABER, E. (1996). Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J. Clin. Invest. 98, 490-496.
33. 33. MANDRIOTA, S.J., MENOUD, P.A., and PEPPER, M.S. (1996). Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/Flk-1 expression in vascular endothelial cells. J. Biol. Chem. 271, 11500-11505.
34. 34. DAVIS SMYTH, T., CHEN, H., PARK, J., PRESTA, L.G., and FERRARA, N. (1996). The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15, 4919-4927.
35. 35. POBER, J.S., SLOWIK, M.R., DE LUCA, L.G., and RITCHIE, A.J. (1993). Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J. Immunol. 150, 5114-5123.
36. 36. ROTHLEIN, R., CZAJKOWSKI, M., O'NEILL, M.M., MARLIN, S.D., MAINOLFI, E., and MERLUZZI, V.J. (1988). Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. J. Immunol. 141, 1665-1669.
37. 37. OROSZ, P., ECHTENACHER, B., FALK, W., RÜSCHOFF, J., WEBER, D., and MÄNNEL, D.N. (1993). Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med. 177, 1391-1398.
38. 38. OROSZ, P., KRÜGER, A., HUBBE, M., RÜSCHOFF, J., VON HOEGEN, P., and MÄNNEL, D.N. (1995). Promotion of experimental liver metastasis by tumor necrosis factor. Int. J. Cancer 60, 867-871.
39. 39. RENARD, N., LIENARD, D., LESPAGNARD, L., EGGERMONT, A., HEIMANN, R., and LEJEUNE, F. (1994). Early endothelium activation and polymorphonucle ar cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int. J. Cancer 57, 656-663.